These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15529064)

  • 1. Vampire bats yield potent clot buster for ischemic stroke.
    Grandjean C; McMullen PC; Newschwander G
    J Cardiovasc Nurs; 2004; 19(6):417-20. PubMed ID: 15529064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury.
    Reddrop C; Moldrich RX; Beart PM; Farso M; Liberatore GT; Howells DW; Petersen KU; Schleuning WD; Medcalf RL
    Stroke; 2005 Jun; 36(6):1241-6. PubMed ID: 15879331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration.
    Liberatore GT; Samson A; Bladin C; Schleuning WD; Medcalf RL
    Stroke; 2003 Feb; 34(2):537-43. PubMed ID: 12574572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection.
    Schleuning WD
    Haemostasis; 2001; 31(3-6):118-22. PubMed ID: 11910176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desmoteplase as a potential treatment for cerebral ischaemia.
    Patel R; Ispoglou S; Apostolakis S
    Expert Opin Investig Drugs; 2014 Jun; 23(6):865-73. PubMed ID: 24766516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): unique fibrin specificity.
    Schleuning WD; Alagon A; Boidol W; Bringmann P; Petri T; Krätzschmar J; Haendler B; Langer G; Baldus B; Witt W
    Ann N Y Acad Sci; 1992 Dec; 667():395-403. PubMed ID: 1309059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.
    Adibhatla RM; Hatcher JF
    CNS Neurol Disord Drug Targets; 2008 Jun; 7(3):243-53. PubMed ID: 18673209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration.
    Witt W; Maass B; Baldus B; Hildebrand M; Donner P; Schleuning WD
    Circulation; 1994 Jul; 90(1):421-6. PubMed ID: 8026028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
    Kruithof EK; Schleuning WD
    Thromb Haemost; 2004 Sep; 92(3):559-67. PubMed ID: 15351852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of tissue plasminogen activator in acute ischemic stroke.
    Hatcher MA; Starr JA
    Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
    Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serine-proteases as plasminogen activators in terms of fibrinolysis.
    Flemmig M; Melzig MF
    J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activation-based thrombolysis for ischaemic stroke: the diversity of targets may demand new approaches.
    Medcalf RL
    Curr Drug Targets; 2011 Nov; 12(12):1772-81. PubMed ID: 21707475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.
    Maiser SJ; Georgiadis AL; Suri MF; Vazquez G; Lakshminarayan K; Qureshi AI
    Int J Stroke; 2011 Feb; 6(1):25-32. PubMed ID: 21205237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.
    Grotta JC; Burgin WS; El-Mitwalli A; Long M; Campbell M; Morgenstern LB; Malkoff M; Alexandrov AV
    Arch Neurol; 2001 Dec; 58(12):2009-13. PubMed ID: 11735774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic treatment of acute ischemic stroke.
    Meschia JF; Miller DA; Brott TG
    Mayo Clin Proc; 2002 Jun; 77(6):542-51. PubMed ID: 12059124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activation and thrombolysis for ischemic stroke.
    Medcalf RL; Davis SM
    Int J Stroke; 2012 Jul; 7(5):419-25. PubMed ID: 22463085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinolytic treatment for acute ischaemic stroke.
    Mazumdar A; Derdeyn CP
    Expert Opin Pharmacother; 2006 Feb; 7(3):287-96. PubMed ID: 16448323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.
    Lapchak PA; Araujo DM; Song D; Wei J; Zivin JA
    Stroke; 2002 May; 33(5):1411-5. PubMed ID: 11988623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clot penetration and retention by plasminogen activators promote fibrinolysis.
    Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
    Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.